Zimmer Biomet Holdings, Inc. filings document a public medical technology company with common stock listed under ZBH and several registered notes listed on the New York Stock Exchange. Recent 8-K reports cover quarterly and annual operating results, updated financial guidance, executive officer departures and interim finance leadership, debt securities, and completed acquisition activity.
The company's proxy and event filings disclose board and executive compensation matters, governance votes, Section 12(b) securities, material agreements, senior unsecured debt obligations, and exhibits tied to earnings releases. These records frame Zimmer Biomet's capital structure, leadership changes, shareholder governance and financial reporting for its orthopedic and musculoskeletal technology business.
HIGGINS ARTHUR J reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Arthur J. Higgins received a grant of 308.711 Phantom Stock Units on March 31, 2026 under the company’s Deferred Compensation Plan for Non-Employee Directors. Each unit is convertible on a 1-for-1 basis with common stock but is to be settled in cash.
The units are scheduled to be paid in ten annual installments, beginning within sixty days after the end of the calendar year in which Higgins’ service as a director ends. Following this award and prior accruals, including 99.385 units from dividend reinvestment on January 30, 2026, he holds 36,375.195 phantom stock units.
Kurdikar Devdatt reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Devdatt Kurdikar received a grant of 154.356 Phantom Stock Units, each tied 1-for-1 to common shares. These units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors at a stated price of $0.0000 per unit.
Following this award, Kurdikar holds a total of 1,928.847 Phantom Stock Units. The units, including 4.508 accrued through dividend reinvestment on January 30, 2026, are scheduled to be settled in shares of Zimmer Biomet common stock within sixty days after his service as a director ends.
HAGEMANN ROBERT reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings, Inc. director Robert Hagemann reported receiving a grant of 308.711 Phantom Stock Units on March 31, 2026. These units are tied 1-for-1 to the company’s common stock value and increase his deferred balance to 31,982.841 units.
The units were accrued under Zimmer Biomet’s Deferred Compensation Plan for Non-Employee Directors and will be settled in cash in five annual installments after his board service ends. His balance also includes 87.178 phantom units added earlier under the plan’s dividend reinvestment provision.
Farrell Michael J. reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Michael J. Farrell reported an award of phantom stock units under the company’s Deferred Compensation Plan for Non-Employee Directors. He received 420.97 phantom stock units tied on a 1-for-1 basis to common stock, bringing his total phantom stock holdings to 18,245.033 units.
The phantom stock units are cash-settled in a lump sum within sixty days after he ceases serving as a director. His total includes 48.381 phantom stock units accrued on January 30, 2026 through the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. is asking shareholders to vote at its May 22, 2026 virtual annual meeting on four key items: electing 10 directors, ratifying PricewaterhouseCoopers as auditor for 2026, approving executive pay on an advisory basis, and a shareholder proposal for an independent board chairman.
The Board highlights a largely independent, skills-diverse slate, strong governance features such as majority voting, proxy access, board evaluations and stock ownership guidelines, and an enhanced Lead Independent Director role when the CEO also serves as Chairman. The company reports 2025 net sales growth of 7.2%, aided by acquisitions and new products, and explains that over 90% of the CEO’s 2025 target pay was performance-based, with annual bonuses and performance stock units tied to constant currency revenue growth, adjusted earnings, free cash flow and relative total shareholder return.
Zimmer Biomet Holdings Inc ownership update: The Vanguard Group filed Amendment No. 9 to a Schedule 13G/A disclosing that it beneficially owns 0 shares of Common Stock, representing 0%. The filing explains an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report holdings separately in reliance on SEC Release No. 34-39538. The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported an open-market sale of company stock. She sold 2,650 shares of common stock at an average price of $94.66 per share. After this transaction, she directly holds 10,224 shares of Zimmer Biomet common stock.
ZBH submitted a Form 144 listing proposed transactions in Common Stock tied to restricted stock vesting events. The filing lists vesting entries dated 03/06/2025, 02/20/2026, 02/25/2026, and 03/06/2026 with quantities including 1, 1,162, 1,423, and 64 shares respectively. The excerpt names Fidelity Brokerage Services LLC as a broker/agent and references the NYSE.
Zimmer Biomet Holdings Exec VP & CFO Suketu Upadhyay exercised restricted stock units into 14,776 shares of common stock on March 6, 2026. To cover tax obligations on this RSU vesting, 6,576 shares were withheld by the company at $92.54 per share. After these compensation-related transactions, Upadhyay directly holds 69,485 shares of Zimmer Biomet common stock.